New Diabetes Strategy Combines a Drug Class, Fasting, and Early Risk Tests to Guard Heart, Kidneys and Liver

Key takeaways

• SGLT‑2 inhibitors can lower heart and kidney stress in type 1 diabetes, but they raise the chance of diabetic ketoacidosis (DKA) and need strict safety steps [1].
• Intermittent fasting cuts body fat in both men and women, yet its ability to stop fatty liver and scarring depends on ketone production and works best in males [2].
• Measuring how well beta cells (the insulin‑making cells) respond to a stimulus can spot people with a single autoantibody who are at high risk of progressing to full‑blown type 1 diabetes [3].

How SGLT‑2 inhibitors may protect the heart and kidneys

Researchers have begun to test SGLT‑2 inhibitors in type 1 diabetes to see if they also shield the heart and kidneys from damage [1]. Early data suggest the drugs can improve surrogate markers—measurements that hint at future disease—such as reduced albumin loss in urine, a sign of kidney strain [1]. Because type 1 diabetes patients already risk DKA, a serious condition where the body builds up dangerous acids called ketones, any trial of SGLT‑2 inhibitors must watch for this side effect [1]. Protocols that limit DKA have been drafted, but solid proof that they work is still missing [1]. The authors propose using smaller, surrogate‑outcome trials to move the field forward while keeping safety front‑and‑center [1].

Why intermittent fasting works differently for men and women

In a mouse study, IF lowered overall body fat in both sexes, showing that the diet can trim weight without relying on ketone (a fuel made when the body burns fat) production [2]. However, the study also found that the liver benefits—less fat buildup (steatosis) and reduced scarring (fibrosis)—were linked to ketone generation, and this link appeared only in male mice [2]. Female mice showed only modest liver changes, suggesting a “ketogenesis‑inflammation‑fibrosis axis” that is sex‑specific [2].

Spotting high‑risk people before full diabetes hits

Adding a test of beta‑cell function—how well those cells release insulin when stimulated—can separate a tiny high‑risk group from a larger low‑risk group [3]. Using data‑driven cutoffs that combine age, autoantibody type and the beta‑cell test, researchers identified a subset with more than a 50 % chance of progressing within two years, while the majority had less than a 10 % chance over five years [3].

What remains unknown

The SGLT‑2 inhibitor data rely on surrogate outcomes and lack large, event‑based trials in type 1 diabetes [1]. The fasting study was done in mice, so human results may differ, especially regarding the sex‑specific liver effects [2]. The beta‑cell profiling work used statistical cutoffs that need validation in broader populations [3].